The Drug Repurposing Market is expected to register a CAGR of 15% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Drug Repurposing Market report is segmented by disease indication into Oncology, CNS Diseases, and Neurodegenerative Diseases. The end-user segment includes Hospitals and Ambulatory Surgical Centers. The market evaluation is presented in US$ for the above segmental analysis. The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.
The report Drug Repurposing Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
The regional trends and factors influencing the Drug Repurposing Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Drug Repurposing Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2024 | US$ XX million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2025 - 2031) | 15% |
| Historical Data | 2021-2023 |
| Forecast period | 2025-2031 |
| Segments Covered |
By Disease Indication
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Drug Repurposing Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Drug Repurposing Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The research report on the Drug Repurposing Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
The leading players of the market are: Astellas Pharma Inc., Biovista, Novartis AG, AbbVie Inc., Pfizer Inc., Allergan Plc., NuMedii, Abbott Healthcare, Hoffmann-La Roche, Johnson & Johnson.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
The increasing adoption of artificial intelligence and machine learning will revolutionize the identification of novel drug indications. Advanced algorithms can analyze vast datasets to uncover hidden patterns and potential therapeutic applications for existing drugs. Moreover, personalized medicine will increasingly drive the development of repurposed drugs tailored to specific patient populations. Genomic and other patient-specific data are leveraged for researchers to identify the best repurposed drugs suitable for a particular patient.
Drug Repurposing Market is expected to grow at a CAGR of 15% between 2023-2031
Several factors push the drug repurposing market forward. The global healthcare expense is increasing, and the prevalence of chronic diseases is rising that requires innovative and cost-effective therapeutic solutions. Repositioning existing drugs is an easier and more economical solution than traditional drug development. This growing awareness of the promise of artificial intelligence and machine learning in drug discovery has fast-tracked the identification of new therapeutic uses for already existing drugs. The two technologies allow researchers to process vast amounts of biological and clinical data to reveal novel drug-target interactions. Several trends are shaping the future of drug repurposing.